Cantor Fitzgerald Forecasts Strong Price Appreciation for Supernus Pharmaceuticals (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals (NASDAQ:SUPN) had its price target lifted by Cantor Fitzgerald from $46.00 to $63.00 in a research note published on Tuesday,Benzinga reports. The firm currently has an overweight rating on the specialty pharmaceutical company’s stock.

Several other research analysts have also weighed in on SUPN. Zacks Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, September 17th. Piper Sandler increased their price objective on Supernus Pharmaceuticals from $36.00 to $40.00 and gave the stock a “neutral” rating in a research report on Friday, August 29th. Finally, Wall Street Zen upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, Supernus Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $51.50.

Supernus Pharmaceuticals Stock Performance

Shares of Supernus Pharmaceuticals stock opened at $47.96 on Tuesday. The firm has a market capitalization of $2.69 billion, a price-to-earnings ratio of 41.70 and a beta of 0.78. Supernus Pharmaceuticals has a fifty-two week low of $29.16 and a fifty-two week high of $48.64. The stock has a 50 day moving average of $43.23 and a 200 day moving average of $36.00.

Insider Buying and Selling at Supernus Pharmaceuticals

In other news, CEO Jack A. Khattar sold 140,000 shares of the stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $42.02, for a total value of $5,882,800.00. Following the sale, the chief executive officer directly owned 1,030,183 shares in the company, valued at approximately $43,288,289.66. This trade represents a 11.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Frederick M. Hudson sold 7,457 shares of the stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $42.26, for a total value of $315,132.82. Following the completion of the sale, the director owned 46,307 shares in the company, valued at approximately $1,956,933.82. The trade was a 13.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 302,841 shares of company stock valued at $13,361,449. Corporate insiders own 8.80% of the company’s stock.

Institutional Trading of Supernus Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Financial Management Professionals Inc. acquired a new stake in shares of Supernus Pharmaceuticals in the first quarter valued at $30,000. Versant Capital Management Inc raised its stake in shares of Supernus Pharmaceuticals by 6,931.3% in the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company’s stock valued at $37,000 after acquiring an additional 1,109 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Supernus Pharmaceuticals in the first quarter valued at $41,000. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Supernus Pharmaceuticals in the first quarter valued at $46,000. Finally, EverSource Wealth Advisors LLC acquired a new stake in shares of Supernus Pharmaceuticals in the second quarter valued at $51,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.